William D. Figg

Research interests

Publications

• Selumetinib in Children with Inoperable Plexiform Neurofibromas

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa1912735

• Antibody–drug conjugates for cancer

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)31774-x

• Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.72.1340

• Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma

  Journal of Hepatology · 2016 · https://doi.org/10.1016/j.jhep.2016.10.029

• Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma

  JAMA Oncology · 2015 · https://doi.org/10.1001/jamaoncol.2015.2010

• Redistribution, Hyperproliferation, Activation of Natural Killer Cells and CD8 T Cells, and Cytokine Production During First-in-Human Clinical Trial of Recombinant Human Interleukin-15 in Patients With Cancer

  Journal of Clinical Oncology · 2014 · https://doi.org/10.1200/jco.2014.57.3329

• Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

  Blood · 2011 · https://doi.org/10.1182/blood-2010-10-312603

• Angiogenesis Inhibitors: Current Strategies and Future Prospects

  CA A Cancer Journal for Clinicians · 2010 · https://doi.org/10.3322/caac.20075

• Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors

  Expert Review of Anticancer Therapy · 2010 · https://doi.org/10.1586/era.10.88

• A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer

  Clinical Cancer Research · 2010 · https://doi.org/10.1158/1078-0432.ccr-10-1725

• Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.21.6150

• Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.10.8332

• Peripheral Neuropathy Induced by Paclitaxel: Recent Insights and Future Perspectives

  Current Neuropharmacology · 2006 · https://doi.org/10.2174/157015906776359568

• Drug interactions in cancer therapy

  Nature reviews. Cancer · 2006 · https://doi.org/10.1038/nrc1887

• Phase I and Pharmacokinetic Study of MS-275, a Histone Deacetylase Inhibitor, in Patients With Advanced and Refractory Solid Tumors or Lymphoma

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.02.188

• Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

  Clinical Cancer Research · 2005 · https://doi.org/10.1158/1078-0432.ccr-04-2291

• Thalidomide

  The Lancet · 2004 · https://doi.org/10.1016/s0140-6736(04)16308-3

• Herbal Remedies in the United States: Potential Adverse Interactions With Anticancer Agents

  Journal of Clinical Oncology · 2004 · https://doi.org/10.1200/jco.2004.08.182

• Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer

  Proceedings of the National Academy of Sciences · 2000 · https://doi.org/10.1073/pnas.180329197

• Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

  Journal of Clinical Oncology · 1999 · https://doi.org/10.1200/jco.1999.17.11.3461

• Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

  Journal of Clinical Oncology · 1998 · https://doi.org/10.1200/jco.1998.16.9.2986

• Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.

  PubMed · 1996

Current projects

No projects listed.